Exploring Arcturus Therapeutics Holdings Inc. (ARCT) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Arcturus Therapeutics and why? With a market cap of $377.32 million as of April 2024, and a share price of $11.87, understanding the investor landscape can provide critical insights. Are institutional investors leading the charge, or is it a surge in retail interest driving the stock? Considering that Arcturus Therapeutics reported a revenue of $6.7 million for the year 2024, against a cost of revenue of $2.1 million, and research and development expenses of $79.7 million, how are these financial dynamics influencing investor decisions? Dive in to uncover the profiles of key investors and the factors shaping their investment strategies in Arcturus Therapeutics.

Arcturus Therapeutics Holdings Inc. (ARCT) Who Invests in [Company Name] and Why?

Arcturus Therapeutics Holdings Inc. (ARCT), founded in 2013 and based in San Diego, California, is a clinical-stage mRNA medicines and vaccines company. It focuses on developing infectious disease vaccines and treatments for liver and respiratory rare diseases. As of April 17, 2025, the share price of Arcturus Therapeutics Holdings Inc. is $10.53 per share, with a market cap of $285.57 million.

Understanding the investor profile of Arcturus Therapeutics provides insights into the market's perception of the company's potential and risks. Key investor types include institutional investors, retail investors, and hedge funds. As of Q4 2023, institutional investors owned 84.7% of the total outstanding shares.

Here's a breakdown of the key investor types and their motivations:

• Institutional Investors: These include mutual funds, pension funds, and insurance companies. As of December 31, 2024, the top institutional holders of Arcturus Therapeutics include:
  • Federated Hermes, Inc.: 4.69 million shares (17.31%) valued at $59.94 million.
  • BlackRock Inc.: 2.99 million shares (11.02%) valued at $38.18 million.
  • Sumitomo Mitsui Trust Holdings, Inc.: 2.07 million shares (7.61%) valued at $26.37 million.
  • Nikko Asset Management Americas, Inc.: 2.07 million shares (7.61%) valued at $26.37 million.
  • ARK Investment Management, LLC: 1.93 million shares (7.13%) valued at $24.70 million.
  These investors are attracted to Arcturus Therapeutics due to its innovative mRNA technology, potential for growth in the vaccine market, and its intellectual property portfolio.
• Retail Investors: These are individual investors who buy and sell shares for their own accounts. While their collective impact can be significant, their individual holdings are typically smaller than those of institutional investors.
• Hedge Funds: These are investment partnerships that use pooled funds and employ different strategies to earn active return, or alpha, for their investors. Hedge funds often invest in Arcturus for short-term gains, taking advantage of volatility and news-driven price movements.

Investment motivations vary among investor types but generally focus on Arcturus Therapeutics' growth prospects, technological advancements, and market position.

The primary attractions for investors include:

• Growth Prospects: Arcturus Therapeutics is poised for significant growth, driven by its mRNA development pipeline, including key products like Kostaive. The European Commission's approval of Kostaive enhances the company's credibility and lays the groundwork for potential revenue exceeding $500 million within five years of product launch.
• Innovative Technology: The company's proprietary self-amplifying mRNA (SAM-RNA) technology and LUNAR lipid-mediated delivery system are key differentiators. These technologies allow for longer antigen production from lower doses, potentially enhancing vaccine safety and efficacy.
• Strategic Partnerships: Collaborations with companies like CSL Seqirus provide financial support and leverage global distribution networks.
• Strong Intellectual Property Portfolio: Arcturus' technologies are protected by an extensive patent portfolio, with 209 patents and patent applications issued in the U.S., Europe, Japan, China, and other countries.

Investors in Arcturus Therapeutics employ various strategies, including long-term holding, short-term trading, and value investing.

Here's a brief overview of these strategies:

• Long-Term Holding: Investors adopting this strategy hold shares for an extended period, banking on the company's long-term growth potential and pipeline development.
• Short-Term Trading: Traders capitalize on short-term price fluctuations driven by news, clinical trial results, and market sentiment.
• Value Investing: Value investors seek to invest in companies that they believe are undervalued by the market, based on fundamental analysis and future growth prospects.

The following table summarizes the changes in institutional ownership of Arcturus Therapeutics:

Overall, the investor profile of Arcturus Therapeutics is diverse, with a strong presence of institutional investors attracted to the company's innovative technology and growth prospects. While hedge funds and retail investors contribute to the trading volume and market dynamics, the long-term success of Arcturus Therapeutics will depend on its ability to execute its clinical programs and commercialize its products.

For more insights into Arcturus Therapeutics, explore: Mission Statement, Vision, & Core Values of Arcturus Therapeutics Holdings Inc. (ARCT).

Arcturus Therapeutics Holdings Inc. (ARCT) Institutional Ownership and Major Shareholders of Arcturus Therapeutics Holdings Inc. (ARCT)

Institutional ownership in Arcturus Therapeutics Holdings Inc. (ARCT) reflects the degree of confidence that large financial organizations have in the company's potential. Tracking these ownership patterns can provide valuable insights into market sentiment and potential stock performance. As of the latest available data, several major institutional investors have significant holdings in Arcturus Therapeutics Holdings Inc. (ARCT).

Here’s a breakdown of what you should know about institutional investors of Arcturus Therapeutics Holdings Inc. (ARCT):

• Top Institutional Investors: The largest institutional investors include well-known firms that manage substantial assets. These firms often conduct extensive research before investing, and their decisions can influence market perception.
• Changes in Ownership: Monitoring whether these institutions are increasing or decreasing their positions can indicate their evolving outlook on the company.
• Impact of Institutional Investors: Large institutional investors can significantly affect Arcturus Therapeutics Holdings Inc. (ARCT)'s stock price and strategic direction through their investment decisions and engagement with company management.

While specific, up-to-the-minute details on shareholdings can fluctuate, examining the trends in institutional ownership provides a macroscopic view of investor confidence in Arcturus Therapeutics Holdings Inc. (ARCT). Always refer to the most recent filings and financial news for the most accurate data.

Detailed information on major shareholders and their respective holdings can often be found in regulatory filings, such as 13F filings submitted to the Securities and Exchange Commission (SEC). These filings provide a quarterly snapshot of the equity positions held by institutional investment managers with over $100 million in assets under management.

Here's a general overview of how institutional investors might influence Arcturus Therapeutics Holdings Inc. (ARCT):

• Price Stability: Large institutional holdings can sometimes reduce stock price volatility due to the size and stability of their positions.
• Strategic Influence: Major shareholders may engage with the company’s board and management, influencing strategic decisions and corporate governance.
• Market Confidence: An increase in institutional ownership can signal positive market sentiment, attracting further investment.

Review the financial health of Arcturus Therapeutics Holdings Inc. (ARCT) to make wise investment decisions: Breaking Down Arcturus Therapeutics Holdings Inc. (ARCT) Financial Health: Key Insights for Investors

Arcturus Therapeutics Holdings Inc. (ARCT) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Arcturus Therapeutics Holdings Inc. (ARCT) is crucial for assessing the company's stability, growth potential, and strategic direction. Key investors can significantly influence company decisions and stock movements through their holdings and activities.

As of April 2025, Arcturus Therapeutics has a substantial institutional ownership base. According to Fintel, 354 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities and Exchange Commission (SEC), holding a total of 30,909,846 shares.

Here are some of the top institutional shareholders of Arcturus Therapeutics Holdings Inc. (ARCT) and their influence:

• Federated Hermes, Inc.: As a major shareholder, Federated Hermes' investment decisions can significantly impact Arcturus Therapeutics' stock performance and investor confidence. According to WallStreetZen, Federated Hermes Inc. holds 17.31% of shares, corresponding to 4,694,060 shares valued at $54.36 million.
• BlackRock, Inc.: BlackRock's substantial holdings often lead to significant influence over company policies and strategic decisions. WallStreetZen reports BlackRock Inc. holds 11.02% of shares, with 2,989,601 shares valued at $34.62 million.
• ARK Investment Management LLC: Known for its focus on innovative and disruptive companies, ARK Investment Management's investment in Arcturus signals confidence in the company's mRNA technology and potential for growth. According to Yahoo Finance, ARK Investment Management, LLC, holds 1.93 million shares as of December 31, 2024, representing 7.13% of the company, valued at $24,695,278.
• Vanguard Group Inc: As one of the largest investment management companies globally, Vanguard's investment provides stability and long-term confidence in Arcturus Therapeutics. Yahoo Finance data indicates Vanguard Group Inc holds 1.68 million shares as of December 31, 2024, accounting for 6.21%, valued at $21,511,844.
• Nikko Asset Management Americas, Inc.: Nikko Asset Management Americas, Inc. holds 7.61% of shares, corresponding to 2,065,050 shares valued at $23.91 million.
• Sumitomo Mitsui Trust Holdings, Inc.: Sumitomo Mitsui Trust Holdings, Inc. holds 7.61% of shares, corresponding to 2,065,050 shares valued at $23.91 million.
• State Street Corp: State Street Corporation holds 1.33 million shares as of December 31, 2024, accounting for 4.89%, valued at $16,935,038.

In addition to institutional investors, insiders also hold a significant portion of Arcturus Therapeutics. Joseph E. Payne is the largest individual shareholder, owning 1.48 million shares, representing 5.46% of the company, with shares currently valued at $17.14 million.

Recent moves by these investors, as indicated by 13F filings, reveal shifts in sentiment and portfolio allocations:

• Schonfeld Strategic Advisors LLC increased its holdings by 129.7%, acquiring 849,081 shares valued at $14.41 million as of February 14, 2025.
• MPM Bioimpact LLC increased its position by 109.5%, with holdings of 459,943 shares valued at $7.81 million as of February 17, 2025.
• Dimensional Fund Advisors LP holds 707,404 shares as of February 14, 2025.

Conversely, some institutions have reduced their positions:

• Bank of America Corp DE decreased its holdings by 82.5%, with 27,712 shares valued at $470K as of February 17, 2025.
• BNP Paribas Financial Markets reduced its stake by 82.7%, holding 2,738 shares valued at $46K as of February 17, 2025.

Here is a summary of Arcturus Therapeutics Holdings Inc. (ARCT) Ownership:

The collective actions of these major investors can drive stock volatility and influence the company's access to capital. Monitoring these ownership trends is essential for understanding the potential trajectory of Arcturus Therapeutics. Keep in mind that the share price as of April 17, 2025, was $10.53 per share, and the market capitalization was $285.57 million.

For further insights into Arcturus Therapeutics' mission, vision, and core values, refer to: Mission Statement, Vision, & Core Values of Arcturus Therapeutics Holdings Inc. (ARCT).

Arcturus Therapeutics Holdings Inc. (ARCT) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Arcturus Therapeutics Holdings Inc. (ARCT). Recent market behavior, coupled with analyst perspectives, provides valuable insights into the company's future trajectory.

Investor Sentiment: Evaluating the sentiment of major shareholders towards Arcturus Therapeutics Holdings Inc. (ARCT) provides a glimpse into the perceived value and prospects of the company. While specific sentiment details (positive, neutral, or negative) can fluctuate, monitoring significant shareholder actions is key. Institutional ownership often signals confidence in long-term growth, whereas decreased holdings might indicate concerns or shifts in investment strategy. Analyzing these movements helps to gauge overall investor confidence.

Recent Market Reactions:

The stock market's response to changes in ownership or large investor moves can significantly impact Arcturus Therapeutics Holdings Inc. (ARCT)'s stock price. Positive reactions typically follow announcements of increased institutional investment or favorable analyst ratings, reflecting increased confidence in the company's prospects. Conversely, negative reactions may occur if major investors reduce their positions or if the company faces setbacks. Keeping track of these market reactions offers insight into how the investment community perceives the value of Arcturus Therapeutics Holdings Inc. (ARCT) and its future potential.

• Positive Market Reactions: Often occur when major investors increase their stakes, or when analysts release favorable ratings.
• Negative Market Reactions: Can arise from reduced investor positions or company setbacks.

Analyst Perspectives: Analyst insights play a crucial role in shaping investor perception of Arcturus Therapeutics Holdings Inc. (ARCT). These experts assess the company's financial performance, pipeline progress, and market opportunities to provide recommendations and price targets. Their analyses often influence investment decisions, making it essential to monitor their reports and ratings. A consensus of positive analyst outlooks can drive investor confidence and stock appreciation, while negative perspectives may lead to caution or sell-offs.

Key factors considered by analysts typically include:

• Pipeline Developments
• Financial Performance
• Market Opportunities

For instance, if analysts project strong growth based on promising clinical trial results, it could lead to increased investor interest. Conversely, concerns about regulatory hurdles or competition could dampen enthusiasm.

Changes in institutional ownership can provide insights into market sentiment. For example, major institutional investors might adjust their holdings based on factors such as:

• Company Performance
• Pipeline Developments
• Broader Market Conditions

Significant shifts in institutional ownership can signal changing confidence levels. Monitoring these changes can help investors understand the broader market sentiment toward Arcturus Therapeutics Holdings Inc. (ARCT).

Here is a hypothetical example of institutional ownership changes and their potential impact:

To delve deeper into Arcturus Therapeutics Holdings Inc. (ARCT)'s financial standing, explore: Breaking Down Arcturus Therapeutics Holdings Inc. (ARCT) Financial Health: Key Insights for Investors